Evaluate the Safety and Efficacy of Dura Sealant Patch in Reducing CSF Leakage Following Elective Cranial Surgery (ENCASE II)

Overview

Información sobre este estudio

The purpose of this study is to clinically assess the safety and effectiveness of LIQOSEAL® as a means of reducing intra-, as well as post-operative, CSF leakage in patients undergoing elective cranial intradural surgery with a dural closure procedure to show noninferiority compared to a control group.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

pre-operative

1. Subjects who are able to provide written informed consent prior to participating in
the clinical investigation.

2. Subjects who are ≥ 18 years old.

3. Subjects who are able to comply with the follow-up or other study requirements.

4. Subjects wo are planned for elective surgery including a trepanation to reach the
subdural infratentorial space (with lower limit of incision defined as the lower edge
of C2) in whom a dural incision will be closed.

5. Female subjects of child bearing potential must agree to use a form of contraception
from the time of signing the informed consent form through 90 days post-surgery.

intra-operative

1. Subjects with surgical wound classification Class I/Clean.

2. Subjects with minimally 5 mm of dural space surrounding dural opening.

Exclusion Criteria:

pre-operative

1. Female subjects who are pregnant or breastfeeding.

2. Subjects with an assumed impaired coagulation due to medication or otherwise.

3. Subjects suspected of an infection requiring antibiotics.

4. Subjects with any type of dural diseases in planned dural closure area.

5. Subjects requiring re-opening of planned surgical area within 90 days after surgery.

6. Subjects with a known allergy to any of the components (Lactide-Caprolactone
co-polyester; Butanediol-BDI co-polyurethane; Polyethylene glycol Succinimidyl
Gluterate; Disodium hydrogen phosphate or D&C Green No 6) of LIQOSEAL®.

7. Subjects who previously received a LIQOSEAL®.

8. Subjects who previously participated in this study or any investigational drug or
device study within 30 days of screening.

9. Subjects with a presence of hydrocephalus.

10. Subjects with contra-indication to MRI [cardiac pacemaker or defibrillator, severe
claustrophobia, injured by a metallic object that was not removed, cochlear (ear)
implants, metallic implants [e.g. knee replacement].

intra-operative

1. Subjects in whom elevation of PEEP has a potential detrimental effect.

2. Subjects who will require a CSF drain, electrodes or other devices passing the dural
layer or extra to intracranial bypass surgery.

3. Subjects who have primary closure of the dura mater with synthetic, nonautologous or
autologous material other than galea.

4. Subjects in whom no intra-operative CSF leakage is present after primary closure of
the dura mater with elevation of PEEP.

5. Subjects who after primary closure (including galea, if applicable) of the dura mater
have a gap > 3 mm.

6. Subjects whom dural opening size including 5 mm margin exceeds patch size (8 x 8 cm).

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 8/24/22. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

Jamie VanGompel, M.D.

Cerrado para la inscripción

Jacksonville, Fla.

Investigador principal de Mayo Clinic

Kaisorn Chaichana, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available
.
CLS-20521247

Mayo Clinic Footer